Legend Biotech Competitors and Similar CompaniesClear all
NovoCure's competitors and similar companies include Novartis, Innovent Biologics, Autolus and Allogene Therapeutics.
 NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Innovent Biologics Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies. |  Autolus Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products. |  Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. | |
Founding Date | Founding Date 2000 | Founding Date 1996 | Founding Date 2011 | Founding Date 2014 | Founding Date 2018 |
Type | Type Public | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Fangshan Qu, CN HQ | Locations London, GB HQ London, GB | Locations South San Francisco, US HQ | |
Employees | Employees 1,488 | Employees 75,883 | Employees 831 | Employees 647 | Employees 2263% decrease |
Valuation ($) | Valuation ($) 1.8 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) 585.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $655.4m (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $75.4m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $166.9m (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods N/A | Cost of goods $86.6m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $488.5m (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit N/A | Gross profit ($10.7m) (FY, 2025) | Gross profit N/A |
Net income | Net income ($136.2m) (FY, 2025) | Net income $14b (FY, 2025) | Net income N/A | Net income ($287.5m) (FY, 2025) | Net income ($190.9m) (FY, 2025) |
Operating ⚠ | |||||
Phase III Trials Products | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 560m | Total funding raised $ 281.7m | Total funding raised $ 532m |
For sources of this data, please see the company profile
View Company Profiles
Novartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyInnovent Biologics
HQ
Fangshan Qu, CN
Employees
831
Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies.
View companyAutolus
HQ
London, GB
Employees
647
Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products.
View companyAllogene Therapeutics
HQ
South San Francisco, US
Employees
226↓ 3% decrease
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View company